PKCiota promotes ovarian tumor progression through deregulation of cyclin e

A. Nanos-Webb, T. Bui, C. Karakas, Dong Zhang, J. P.W. Carey, Gordon Mills, K. K. Hunt, K. Keyomarsi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The high frequency of relapse of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to identify targeted therapies that can improve patient outcomes. The dynamic relationship between cyclin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for therapeutic investigation. We hypothesized that a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway activating PKCiota perpetuates cyclin E deregulation during ovarian tumorigenesis. We observed a positive correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines. Modulation of cyclin E had no effect on PKCiota knockdown/overexpression; however, PKCiota differentially regulated cyclin E expression. In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCiota decreased proliferation, caused a G1 arrest and significantly prolonged overall survival in xenograft mouse models. In vitro, shPKCiota decreased the ability of IGROV cells to grow under anchorage-independent conditions and form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression. Reverse-phase protein array analysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the association between phospho-PKCiota levels and PI3K pathway activation. Inhibitors of PI3K coordinately decreased phospho-PKCiota and cyclin E protein levels. In conclusion, we have identified a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis.

Original languageEnglish (US)
Pages (from-to)2428-2440
Number of pages13
JournalOncogene
Volume35
Issue number19
DOIs
StatePublished - May 12 2016
Externally publishedYes

Fingerprint

Cyclin E
Cyclins
1-Phosphatidylinositol 4-Kinase
Neoplasms
Ovarian Neoplasms
Carcinogenesis
Protein Array Analysis
Heterografts
Protein Isoforms
Therapeutics
Recurrence
Drug Therapy
Cell Line
Survival

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Nanos-Webb, A., Bui, T., Karakas, C., Zhang, D., Carey, J. P. W., Mills, G., ... Keyomarsi, K. (2016). PKCiota promotes ovarian tumor progression through deregulation of cyclin e. Oncogene, 35(19), 2428-2440. https://doi.org/10.1038/onc.2015.301

PKCiota promotes ovarian tumor progression through deregulation of cyclin e. / Nanos-Webb, A.; Bui, T.; Karakas, C.; Zhang, Dong; Carey, J. P.W.; Mills, Gordon; Hunt, K. K.; Keyomarsi, K.

In: Oncogene, Vol. 35, No. 19, 12.05.2016, p. 2428-2440.

Research output: Contribution to journalArticle

Nanos-Webb, A, Bui, T, Karakas, C, Zhang, D, Carey, JPW, Mills, G, Hunt, KK & Keyomarsi, K 2016, 'PKCiota promotes ovarian tumor progression through deregulation of cyclin e', Oncogene, vol. 35, no. 19, pp. 2428-2440. https://doi.org/10.1038/onc.2015.301
Nanos-Webb, A. ; Bui, T. ; Karakas, C. ; Zhang, Dong ; Carey, J. P.W. ; Mills, Gordon ; Hunt, K. K. ; Keyomarsi, K. / PKCiota promotes ovarian tumor progression through deregulation of cyclin e. In: Oncogene. 2016 ; Vol. 35, No. 19. pp. 2428-2440.
@article{60fdcd1b6e164ecbb4b0343a09db1bee,
title = "PKCiota promotes ovarian tumor progression through deregulation of cyclin e",
abstract = "The high frequency of relapse of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to identify targeted therapies that can improve patient outcomes. The dynamic relationship between cyclin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for therapeutic investigation. We hypothesized that a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway activating PKCiota perpetuates cyclin E deregulation during ovarian tumorigenesis. We observed a positive correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines. Modulation of cyclin E had no effect on PKCiota knockdown/overexpression; however, PKCiota differentially regulated cyclin E expression. In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCiota decreased proliferation, caused a G1 arrest and significantly prolonged overall survival in xenograft mouse models. In vitro, shPKCiota decreased the ability of IGROV cells to grow under anchorage-independent conditions and form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression. Reverse-phase protein array analysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the association between phospho-PKCiota levels and PI3K pathway activation. Inhibitors of PI3K coordinately decreased phospho-PKCiota and cyclin E protein levels. In conclusion, we have identified a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis.",
author = "A. Nanos-Webb and T. Bui and C. Karakas and Dong Zhang and Carey, {J. P.W.} and Gordon Mills and Hunt, {K. K.} and K. Keyomarsi",
year = "2016",
month = "5",
day = "12",
doi = "10.1038/onc.2015.301",
language = "English (US)",
volume = "35",
pages = "2428--2440",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "19",

}

TY - JOUR

T1 - PKCiota promotes ovarian tumor progression through deregulation of cyclin e

AU - Nanos-Webb, A.

AU - Bui, T.

AU - Karakas, C.

AU - Zhang, Dong

AU - Carey, J. P.W.

AU - Mills, Gordon

AU - Hunt, K. K.

AU - Keyomarsi, K.

PY - 2016/5/12

Y1 - 2016/5/12

N2 - The high frequency of relapse of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to identify targeted therapies that can improve patient outcomes. The dynamic relationship between cyclin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for therapeutic investigation. We hypothesized that a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway activating PKCiota perpetuates cyclin E deregulation during ovarian tumorigenesis. We observed a positive correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines. Modulation of cyclin E had no effect on PKCiota knockdown/overexpression; however, PKCiota differentially regulated cyclin E expression. In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCiota decreased proliferation, caused a G1 arrest and significantly prolonged overall survival in xenograft mouse models. In vitro, shPKCiota decreased the ability of IGROV cells to grow under anchorage-independent conditions and form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression. Reverse-phase protein array analysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the association between phospho-PKCiota levels and PI3K pathway activation. Inhibitors of PI3K coordinately decreased phospho-PKCiota and cyclin E protein levels. In conclusion, we have identified a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis.

AB - The high frequency of relapse of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to identify targeted therapies that can improve patient outcomes. The dynamic relationship between cyclin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for therapeutic investigation. We hypothesized that a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway activating PKCiota perpetuates cyclin E deregulation during ovarian tumorigenesis. We observed a positive correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines. Modulation of cyclin E had no effect on PKCiota knockdown/overexpression; however, PKCiota differentially regulated cyclin E expression. In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCiota decreased proliferation, caused a G1 arrest and significantly prolonged overall survival in xenograft mouse models. In vitro, shPKCiota decreased the ability of IGROV cells to grow under anchorage-independent conditions and form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression. Reverse-phase protein array analysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the association between phospho-PKCiota levels and PI3K pathway activation. Inhibitors of PI3K coordinately decreased phospho-PKCiota and cyclin E protein levels. In conclusion, we have identified a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=84939446548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939446548&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.301

DO - 10.1038/onc.2015.301

M3 - Article

C2 - 26279297

AN - SCOPUS:84939446548

VL - 35

SP - 2428

EP - 2440

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 19

ER -